Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- PMRJ Introduces “RS Expert Certification System”
April 30, 2013
- PAFSC’s Second Committee Recommends Approval for Chugai’s Breast Cancer Drug Perjeta, Others
April 26, 2013
- Japan-Version NIH: Cabinet HQ to Lay Out Comprehensive Strategy, Integrate R&D Budgets
April 25, 2013
- Bill to Amend PAL Will Be Submitted to Diet in May, as Instructed by PM Abe: Mr Akagawa of PFSB
April 25, 2013
- MHLW Picks Additional Clinical Research Core Hospitals
April 23, 2013
- MHLW May Refuse Applications for Generic Drug Listing from Companies that Fail to Maintain Stable Supplies
April 23, 2013
- Experts on Council for Science and Technology Policy Back Measures to Promote Development of Innovative New Drugs Aiming at Healthy, Long-lived Society
April 19, 2013
- Reorganization of Council for Science and Technology Policy Proposed by Industrial Competitiveness Council to Create Stronger Centralized Authority
April 19, 2013
- First Committee to Discuss Approval of New Gout Treatment Topiroxostat
April 18, 2013
- Committee Finds No Problem with Quality of 8 Generic Versions of Pfizer Japan’s Unasyn-S Kit
April 18, 2013
- “Japanese Version of CTEP” Proposed at 1st Meeting of Expert Council on Future Cancer Research
April 16, 2013
- Growing Concern Over Return to Brand Names for Generics with Advent of Generic Versions of Combination Drugs
April 16, 2013
- PAFSC’s Second Committee to Review Chugai’s Breast Cancer Drug Pertuzumab on April 25
April 15, 2013
- Supreme Court Rejects Damage Claims in Iressa Suits; Govt, AZ Win 8-Year Battle
April 15, 2013
- Generic Roadmap: CSIMC Bill Payer Rep Says New 60% Target Could “Decelerate” Shift
April 12, 2013
- Cost-Effective Assessment Should Be Reflected in Pricing, Not Used as Criterion for Approval: Healthcare Reps at CSIMC
April 12, 2013
- CSIMC OKs NHI Price Listing of JT’s Anti-HIV Drug Stribild on Emergency Basis
April 11, 2013
- New Flu Act to Take Effect on April 13
April 11, 2013
- Japan Launches Strategic Fund for Drug R&D in Developing World
April 10, 2013
- MHLW Issues Order for Improvement to 5 Generic Companies due to GMP Violations by South Korean Supplier
April 9, 2013
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…